Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma

NCT ID: NCT05505461

Last Updated: 2022-08-17

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-31
• Study Completion Date: 2027-12-31

Brief Summary

The purpose of this study was to evaluate the effect and safety of concurrent PD-1 antibody-based long-term radiotherapy followed by 2 cycles SOX with PD-1 in patients with locally advanced adenocarcinoma of esophagogastric junction.

Detailed Description

The incidence of adenocarcinoma of the esophagogastric junction (AEG) is increasing in Asian countries and Western Contries. Surgical resection is the most important treatment for AEG. However, the recurrence rate is high when surgery is performed alone. The results of CLASSIC, MAGIC, FLOT4, JCOG0501, PRODIGY, RESOLVE, CROSS trial showed that perioperative chemotherapy and pre- or postoperative chemoradiotherapy significantly increase the overall survival rate and disease free survival rate compared to surgery alone. Radiotherapy and immunotherapy can increase sensitivity to each other, and several clinical studies have also showed that PD-1 antibody may significantly prolongs the life.Thus the investigators plan to conduct this clinical trial to evaluate the effect and safety of concurrent PD-1 antibody-based long-term radiotherapy followed by 2 cycles SOX with PD-1 in patients with locally advanced adenocarcinoma of esophagogastric junction.

Subjects will receive long-term radiotherapy (5w) concurrent with PD-1 antibody for 2 cycles, then receive two cycles of SOX regimen combined PD-1 after a week's rest. Surgery will be performed 2 weeks after the last cycle of neoadjuvant treatment. Adjuvant treatment will be started 3 to 8 weeks after surgery, and SOX regimen will be given for 4 cycles.

Conditions

Adenocarcinoma of Esophagogastric Junction

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Neoadjuvant therpy

Neoadjuvant chemoradiation plus SOX and PD-1 antibody

Group Type: EXPERIMENTAL

neoadjuvant Radiation plus SOX and PD-1 antibody

Intervention Type: DRUG

Patients will be given the perioperative treatment as below once recruited:

First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.

The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.

SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery.

Interventions

neoadjuvant Radiation plus SOX and PD-1 antibody

Patients will be given the perioperative treatment as below once recruited:

First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.

The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.

SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery.

Intervention Type: DRUG

Other Intervention Names

Neoadjuvant Chemoradiotherapy plus Immunotherapy

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed adenocarcinoma of esophagogastric junction, and Her-2 negative.

2. Clinically diagnosed stage T3+orN+M0, according to CT/MRI scan.

3. No prior anti-tumor treatment, including surgery, chemotherapy, radiotherapy, and targeted therapy.

4. Eastern Cooperative Oncology Group(ECOG) performance status(PS) 0-1.

5. At least one evaluable lesion in abdominal CT/MRI according to RESIST 1.1 is required.

6. Expected survival ≥6 months.

7. Adequate organ function, Hemoglobin ≥90g/L; White blood cells ≥3.0×109/L; neutrophil count ≥1.5×109/L; Platelets ≥100×109/L; Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault formula); Total bilirubin (TBIL) ≤ 1.5 times the ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤ 2.5 times the ULN; Urine protein < 2+; if urine protein ≥ 2+, 24-hour urine protein quantification shows that protein must be ≤ 1 g.

8. Normal coagulation function, no active bleeding and thrombotic diseases: International Standardized Ratio INR≤1.5×ULN; Partial thromboplastin time APTT≤1.5×ULN; Prothrombin time PT≤1.5ULN;

9. Previous use of anti-tumor Chinese medicines, proprietary Chinese medicines, and immunomodulators (such as thymosin, interleukin, etc.) must be ≥ 2 weeks from the start of the study medication;

10. Female patients should not be pregnant or breast feeding. Male should contraception.

11. Able and willing to give informed consent to participate.

12. Those who are expected to have good compliance.

Exclusion Criteria

1. Existence of other active malignant tumors within 5 years or at the same time.

2. Already received chemotherapy, radiation therapy, targeted or immunotherapy.

3. Have any active autoimmune disease or history of autoimmune disease.

4. Patients with congenital or acquired immunodeficiency.

5. Use of immunosuppressive drugs within 14 days before the study start.

6. Administer live attenuated vaccines within 4 weeks before the study start.

7. Suffering from uncontrolled cardiac clinical symptoms or diseases, such as (1) NYHA II and above heart failure (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) poorly controlled arrhythmia.

8. Patients with past and current interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, etc., and severely impaired lung function.

9. Suffering from active pulmonary tuberculosis.

10. Complicated severe infection within 4 weeks before the the study start, or unexplained fever >38.5°C during the screening period/before the study start.

11. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.

13. Allergic to any drug in this study. 14. Combined with other severe, acute and chronic diseases that may increase the risk of participating.

15.Participators who had been recruited by other clinical trial within three months.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

YE Yingjiang

Director of the department of gastrointestinal surgery

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yingjiang Ye, MD，PhD

Role: PRINCIPAL_INVESTIGATOR

Peking University People's Hospital

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Liyu Zhu, MD

Role: CONTACT

wcwkzlward@163.com

+8610-66583821

Jing Zhou, MD

Role: CONTACT

wcwkzlward@163.com

+8610-66583820

Facility Contacts

Liyu Zhu

Role: primary

wcwkzlward@163.com

+8610-66583821

Other Identifiers

WCWKZL-001

Identifier Type: -

Identifier Source: org_study_id